H3 Biomedicine Competitors and Similar CompaniesClear all

H3 Biomedicine's competitors and similar companies include Tanvex BioPharma, Bluebird Bio, Juno Therapeutics, Tetraphase Pharmaceuticals and centrose.
H3 Biomedicine
H3 Biomedicine
H3 Biomedicine is a biopharmaceutical company that specializes in cancer genomics.
Tanvex BioPharma
Tanvex BioPharma
Tanvex BioPharma (formerly known as Ruenvex Biotech) is a company that manufactures and develops biosimilar and biologic products and drugs.
Bluebird Bio
Bluebird Bio
Bluebird Bio is a developer of gene therapies for severe genetic diseases.
Juno Therapeutics
Juno Therapeutics
Juno Therapeutics is a clinical-stage company, which develops immunotherapies for the treatment of cancer.
Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals is a company leveraging a dynamic drug engine targeted at several significant disease categories.
centrose
centrose
centrose is a biotechnology company engaged in the development and commercialization of antibody drug conjugates (ADCs), targeting disease-related cells.
Founding Date
Founding Date
2011
Founding Date
2013
Founding Date
1992
Founding Date
2013
Founding Date
2006
Founding Date
2007
Type
Type
Subsidiary
Type
Public
Type
Public
Type
Subsidiary
Type
Subsidiary
Type
Private
Tags
Locations
Locations
Cambridge, US HQ
Locations
Taipei, TW HQ
New Taipei, TW
Irvine, US
San Diego, US
San Diego, US
Locations
Somerville, US HQ
Locations
Seattle, US HQ
Göttingen, DE
Göttingen, DE
München, DE
München, DE
Bothell, US
Brisbane, US
Locations
Watertown, US HQ
Waltham, US
Locations
Middleton, US HQ
Employees
Employees
378% decrease
Employees
18910% increase
Employees
32338% decrease
Employees
1373% decrease
Employees
16
Employees
N/A
Twitter followers
Twitter followers
473
Twitter followers
N/A
Twitter followers
10.6 k
Twitter followers
2.4 k
Twitter followers
785
Twitter followers
10

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
NT$61.4m (FY, 2023)
Revenue (est.)
$3.6m (FY, 2022)
Revenue (est.)
$111.9m (FY, 2017)
Revenue (est.)
$7.4m (FY, 2019)
Revenue (est.)
N/A
Net income
Net income
N/A
Net income
(NT$2.1b) (FY, 2023)
Net income
($266.6m) (FY, 2022)
Net income
($437.1m) (FY, 2017)
Net income
($70.1m) (FY, 2019)
Net income
N/A

Funding

Total funding raised
Total funding raised
$ 200m
Total funding raised
$ 346.9m
Total funding raised
$ 409m
Total funding raised
$ 310m
Total funding raised
$ 94.8m
Total funding raised
$ 100k
For sources of this data, please see the company profile

View Company Profiles

Tanvex BioPharma
HQ
Taipei, TW
Employees
189↑ 10% increase

Tanvex BioPharma (formerly known as Ruenvex Biotech) is a company that manufactures and develops biosimilar and biologic products and drugs.

View company
Bluebird Bio
HQ
Somerville, US
Employees
323↓ 38% decrease

Bluebird Bio is a developer of gene therapies for severe genetic diseases.

View company
Juno Therapeutics
HQ
Seattle, US

Juno Therapeutics is a clinical-stage company, which develops immunotherapies for the treatment of cancer.

View company
Tetraphase Pharmaceuticals
HQ
Watertown, US

Tetraphase Pharmaceuticals is a company leveraging a dynamic drug engine targeted at several significant disease categories.

View company